| Mr Scott Edward Ewing, FNP-BC | |
|
1648 Highway 95, Bullhead City, AZ 86442-7906 | |
| (928) 758-4114 | |
| (928) 758-4650 |
| Full Name | Mr Scott Edward Ewing |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Family |
| Location | 1648 Highway 95, Bullhead City, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447787882 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | AP10115 (Arizona) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP10115 (Arizona) | Primary |
| Entity Name | Rta Hospice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982360566 PECOS PAC ID: 7911969829 Enrollment ID: O20130819000605 |
News Archive
Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.
The job of implementing a key Obama administration health reform -;a statewide marketplace where consumers and businesses can buy affordable health insurance-;would be turned over to a non-profit company under proposed legislation announced today by Michigan's Republican Gov. Rick Snyder.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
› Verified 1 days ago
| Entity Name | Southwest Cardiovascular Associates Ahmed Alfafara And Prasad Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205883162 PECOS PAC ID: 7810209525 Enrollment ID: O20150709001657 |
News Archive
Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.
The job of implementing a key Obama administration health reform -;a statewide marketplace where consumers and businesses can buy affordable health insurance-;would be turned over to a non-profit company under proposed legislation announced today by Michigan's Republican Gov. Rick Snyder.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
› Verified 1 days ago
| Entity Name | Compassus Op Of Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336785567 PECOS PAC ID: 3577846922 Enrollment ID: O20200304000096 |
News Archive
Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.
The job of implementing a key Obama administration health reform -;a statewide marketplace where consumers and businesses can buy affordable health insurance-;would be turned over to a non-profit company under proposed legislation announced today by Michigan's Republican Gov. Rick Snyder.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Scott Edward Ewing, FNP-BC 1648 Highway 95, Bullhead City, AZ 86442-7906 Ph: (928) 758-4114 | Mr Scott Edward Ewing, FNP-BC 1648 Highway 95, Bullhead City, AZ 86442-7906 Ph: (928) 758-4114 |
News Archive
Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.
The job of implementing a key Obama administration health reform -;a statewide marketplace where consumers and businesses can buy affordable health insurance-;would be turned over to a non-profit company under proposed legislation announced today by Michigan's Republican Gov. Rick Snyder.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
› Verified 1 days ago